ClinicalTrials.gg

Program

veligrotug

Also written as “Veligrotug”, “AVE1642” and “veligrotrug (LUMVOA™)”.

Its studies are mostly in Graves Ophthalmopathy · Breast Neoplasms · Multiple Myeloma, led by 2 companies.

Furthest: phase 4, since Sep 15, 20267 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viridian Therapeutics51 open or runningphase 4since Sep 15, 2026Dec 15, 2021Apr 2027phase 4 · NCT07832136
Sanofi20 open or runningphase 2since Oct 16, 2008Oct 16, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2008First study: phase 2 study in Breast NeoplasmsNew to SanofiSanofi · NCT00774878 · 18 enrolled · France, Italy, Spain
  2. Oct 29, 2010Phase 1 study in Multiple MyelomaSanofi · NCT01233895 · 26 enrolled · France, Italy
  3. Dec 15, 2021Viridian Therapeutics's first study: phase 3 study in Graves OphthalmopathyNew to Viridian TherapeuticsViridian Therapeutics · NCT05176639 · 113 enrolled · United States, Australia, France and more
  4. Aug 25, 2023Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT06021054 · 188 enrolled · United States, Australia, France and more
  5. Dec 12, 2023Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT06179875 · 139 enrolled · United States, France, Germany and more
  6. Apr 22, 2024Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT06384547 · 231 enrolled · United States, Australia, France and more
  7. Sep 15, 2026Phase 4 study in Graves OphthalmopathyViridian Therapeutics · NCT07832136 · 30 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 4 study in Graves OphthalmopathyViridian Therapeutics · NCT07832136

TargetBeta

IGF1R →read by rule
“A humanized monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R/CD221) ”NCIt, by rule
“Insulin-like growth factor I receptor antagonist”ChEMBL 37, by rule

Other programs on IGF1R

ProgramCompanyFurthest phaseStudies
teprotumumabruleAmgenphase 418
linsitinibruleAstellas Pharmaphase 313
MHB018AruleMinghui Pharmaceuticalphase 36
IBI311ruleInnovent Biologicsphase 35
IBI3031ruleInnovent Biologicsphase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07832136Graves Ophthalmopathy · United States4Not yet recruitingViridian TherapeuticsApr 202730
NCT06384547Graves Ophthalmopathy · United States, Australia, France and more3CompletedViridian TherapeuticsMay 1, 2025231
NCT06179875Graves Ophthalmopathy · United States, France, Germany and more3CompletedViridian TherapeuticsApr 25, 2025139
NCT06021054Graves Ophthalmopathy · United States, Australia, France and more3CompletedViridian TherapeuticsNov 4, 2024188
NCT05176639Graves Ophthalmopathy · United States, Australia, France and more3CompletedViridian TherapeuticsJul 15, 2024113
NCT01233895Multiple Myeloma · France, Italy1CompletedSanofiSep 200826
NCT00774878Breast Neoplasms · France, Italy, Spain2TerminatedSanofiNov 201018

How it is read

Names in the registry

  • “Veligrotug”, 4 entries
  • “AVE1642”, 2 entries
  • “veligrotrug (LUMVOA™)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.